Second-Generation Drug-Eluting Stents in Diabetes (SUGAR) trial: Rationale and study design - 17/03/20
, Pablo Salinas, MD b, 1, Salvatore Brugaletta, MD, PhD c, Josep Gomez-Lara, MD, PhD a, José F. Díaz, MD d, Miguel A. Romero, MD e, Sergio García-Blas, MD f, Raymundo Ocaranza, MD g, Pascual Borde, MD h, Marcelo Jiménez Kockar, MD i, Raul Millan Segovia, MD j, Andrés Íñiguez, MD k, Mar Alameda, MD l, Ramiro Trillo, MD m, Dae Hyun Lee, MD n, Pedro Martín, MD o, María López-Benito, MD p, Araceli Frutos, MD q, José Moreu, MD r, Felipe Hernández-Hernández, MD s, Bruno García del Blanco, MD t, Gerard Roura, MD, PhD a, Xavier Rossello, MD, PhD u, Stuart J. Pocock, MD, PhD v, Antonio Fernández-Ortiz, MD b, Manel Sabate, MD, PhD c, JA Gómez-Hospital, MD, PhD aRésumé |
Aim |
Patients with diabetes mellitus (DM) undergoing percutaneous coronary intervention (PCI) remain at high risk of cardiovascular events despite the use of contemporary drug-eluting stents (DES). This trial aim to compare the clinical efficacy of 2 novel second-generation DES in patients with DM.
Methods and results |
The Second-Generation Drug-Eluting Stents in Diabetes (SUGAR) trial (ClinicalTrials.gov NCT03321032) is an investigator-initiated, prospective, randomized, controlled, multicenter study conducted exclusively in patients with DM. This study allows inclusion of the entire spectrum of patients with DM undergoing PCI, and the only exclusion criteria are shock at presentation, inability to consent or a life expectancy <2 years. A total of 1164 patients will be randomized (1:1, no stratification) at 23 sites in Spain to treatment with polymer-free amphilimus (sirolimus formulated with an amphiphilic carrier) eluting stents versus Onyx-zotarolimus-eluting stents (Biolynx durable polymer and struts with platinum-iridium alloy core). Randomization will be patient-level, so in case of multivessel disease all lesions will be treated with the same stent. The primary end point is target lesion failure, a composite of cardiac death, target vessel–related myocardial infarction, or clinically indicated target lesion revascularization. First co-primary analysis will test non-inferiority at 1 year (80% power, a non-inferiority margin of 4% (1.5 RR) and a type-I-error of 0.05.) and second co-primary analysis will test superiority at 2 years (80% power, 0.05 alpha). Enrollment commenced in December 2017, and inclusion is expected to be completed by December 2019.
Conclusions |
SUGAR is the first randomized head-to head trial comparing second-generation DES in an all-comer diabetic population undergoing PCI.
Le texte complet de cet article est disponible en PDF.Plan
Vol 222
P. 174-182 - avril 2020 Retour au numéro
Article précédent
- Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both
- Keith A.A. Fox, Sonia S. Anand, Victor Aboyans, Martin R. Cowie, E. Sebastian Debus, Uwe Zeymer, Danja Monje, Kai Vogtländer, Robert Lawatscheck, Alain Gay
- Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF)
- James E. Udelson, Gregory D. Lewis, Sanjiv J. Shah, Michael R. Zile, Margaret M. Redfield, John Burnett, Robert S. Mittleman, Albert T. Profy, Jelena P. Seferovic, David Reasner, Marvin A. Konstam
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?